T. Rowe Price Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

T. Rowe Price Associates’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-92,000	Closed	-$80K	–	3052
2024 Q3	$80K	Sell	92,000 -144,100	-61%	-$106K	﹤0.01%	2864
2024 Q2	$83K	Sell	236,100 -42,604	-15%	-$23K	﹤0.01%	2781
2024 Q1	$187K	Buy	278,704 +10,373	+4%	+$7.52K	﹤0.01%	2642
2023 Q4	$146K	Buy	268,331 +3,218	+1%	+$1.48K	﹤0.01%	2640
2023 Q3	$160K	Buy	265,113 +35,290	+15%	+$37.8K	﹤0.01%	2562
2023 Q2	$299K	Buy	229,823 +4,633	+2%	+$6.33K	﹤0.01%	2366
2023 Q1	$397K	Buy	225,190 +65,039	+41%	+$186K	﹤0.01%	2207
2022 Q4	$503K	Buy	160,151 +5,015	+3%	+$19.5K	﹤0.01%	2130
2022 Q3	$761K	Buy	155,136 +8,826	+6%	+$45.3K	﹤0.01%	1907
2022 Q2	$606K	Buy	146,310 +5,700	+4%	+$24.6K	﹤0.01%	2143
2022 Q1	$817K	Buy	140,610 +2,444	+2%	+$14.5K	﹤0.01%	2102
2021 Q4	$1.04M	Buy	138,166 +49,453	+56%	+$430K	﹤0.01%	2020
2021 Q3	$799K	Buy	88,713 +6,881	+8%	+$68K	﹤0.01%	2155
2021 Q2	$980K	Sell	81,832 -7,549	-8%	-$85.5K	﹤0.01%	2077
2021 Q1	$1.12M	Sell	89,381 -51,389	-37%	-$692K	﹤0.01%	2000
2020 Q4	$2.2M	Sell	140,770 -16,633	-11%	-$195K	﹤0.01%	1603
2020 Q3	$1.49M	Hold	157,403	–	–	﹤0.01%	1647
2020 Q2	$1.41M	Sell	157,403 -11,566	-7%	-$107K	﹤0.01%	1655
2020 Q1	$1.08M	Buy	168,969 +47,021	+39%	+$349K	﹤0.01%	1673
2019 Q4	$1.02M	Buy	121,948 +952	+0.8%	+$8.75K	﹤0.01%	1874
2019 Q3	$1.09M	Buy	120,996 +14,928	+14%	+$167K	﹤0.01%	1782
2019 Q2	$1.14M	Buy	106,068 +499	+0.5%	+$5.31K	﹤0.01%	1793
2019 Q1	$1.01M	Buy	105,569 +300	+0.3%	+$3.06K	﹤0.01%	1840
2018 Q4	$1.21M	Sell	105,269 -14,524	-12%	-$180K	﹤0.01%	1727
2018 Q3	$2.03M	Sell	119,793 -802	-0.7%	-$12.2K	﹤0.01%	1618
2018 Q2	$1.71M	Buy	120,595 +57,612	+91%	+$957K	﹤0.01%	1634
2018 Q1	$1.2M	Sell	62,983 -7,817	-11%	-$167K	﹤0.01%	1717
2017 Q4	$1.16M	Sell	70,800 -5,500	-7%	-$81.8K	﹤0.01%	1745
2017 Q3	$1.15M	Sell	76,300 -12,400	-14%	-$137K	﹤0.01%	1761
2017 Q2	$781K	Sell	88,700 -39,500	-31%	-$253K	﹤0.01%	1876
2017 Q1	$667K	Sell	128,200 -15,000	-10%	-$60.2K	﹤0.01%	1952
2016 Q4	$437K	Hold	143,200	–	–	﹤0.01%	2109
2016 Q3	$663K	Buy	143,200 +44,700	+45%	+$227K	﹤0.01%	1902
2016 Q2	$570K	Buy	98,500 +17,900	+22%	+$114K	﹤0.01%	1913
2016 Q1	$488K	Buy	80,600 +17,600	+28%	+$106K	﹤0.01%	1979
2015 Q4	$575K	Sell	63,000 -6,400	-9%	-$49.3K	﹤0.01%	1899
2015 Q3	$391K	Buy	69,400 +7,300	+12%	+$60.2K	﹤0.01%	2053
2015 Q2	$689K	Buy	62,100 +12,000	+24%	+$155K	﹤0.01%	1872
2015 Q1	$786K	Buy	50,100 +3,100	+7%	+$48K	﹤0.01%	1810
2014 Q4	$715K	Hold	47,000	–	–	﹤0.01%	1814
2014 Q3	$507K	Buy	47,000 +9,700	+26%	+$127K	﹤0.01%	1931
2014 Q2	$570K	Hold	37,300	–	–	﹤0.01%	1889
2014 Q1	$674K	Buy	37,300 +4,600	+14%	+$88.7K	﹤0.01%	1803
2013 Q4	$454K	Sell	32,700 -7,100	-18%	-$81.8K	﹤0.01%	1950
2013 Q3	$417K	Hold	39,800	–	–	﹤0.01%	1964
2013 Q2	$311K	Buy	+39,800	New	+$347K	﹤0.01%	2055

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

T. Rowe Price Associates's SGMO Position: Q4 2024 in Review

T. Rowe Price Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2024, closing a stake of 92,000 shares — an estimated $80K sold.

T. Rowe Price Associates first reported a position in SGMO in Q2 2013 and held it in 46 quarters. The position peaked at $2.2M in Q4 2020. 128 funds tracked by Wall St. Rank hold SGMO as of Q4 2024.

T. Rowe Price Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2024 after selling out during the quarter.
T. Rowe Price Associates sold 92,000 SANGAMO THERAPEUTICS INC shares in Q4 2024, an estimated $80K.
T. Rowe Price Associates first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 46 quarters.
T. Rowe Price Associates's SANGAMO THERAPEUTICS INC position peaked at $2.2M in Q4 2020.
128 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.